Every Cure Inc.

Every Cure Inc. is a U.S. nonprofit organization focused on medical research, specifically AI-driven drug repurposing. It received its nonprofit status in 2023 and is classified under the category of Medical Research, N.E.C. (Not Elsewhere Classified) according to the National Taxonomy of Exempt Entities (NTEE)[1][2].

Mission

The mission of Every Cure Inc. is to unlock the full potential of existing medicines to treat every disease and every patient they possibly can[3][4]. This approach is inspired by the personal experience of its co-founder, Dr. David Fajgenbaum, who discovered a new use for an existing drug in treating his Castleman Disease[3].

Leadership

Key figures associated with Every Cure Inc. include:

• Dr. David Fajgenbaum (Co-founder, President)
• Dr. Grant Mitchell (Leader)
• Other notable members include Tanisha Carino, Tracey Sikora, Robert Battista, Freda Lewis Hall, Robert McDonald, and Tania Simoncelli. None of the key employees or officers receive compensation[1].

Financial Overview

As of the fiscal year ending in December 2023, the organization reported:

• Total Revenue: Primarily from contributions ($2,433,649), with a small portion from investment income ($9,736)[1].
• Total Expenses: Include salaries and wages as a significant component, though specific figures for salary compensation are not reported[1].
• Assets and Liabilities: The organization holds total assets of $3,270,374 and total liabilities of $966,302[1].

Activities

Every Cure Inc. focuses on AI-driven drug repurposing, aiming to scale up this approach to help patients globally by discovering new uses for approved drugs[3].

[1] https://projects.propublica.org/nonprofits/organizations/920240717 [2] https://www.every.org/every-cure-inc [3] https://everycure.org [4] https://www.guidestar.org/profile/92-0240717 [5] https://www.charitynavigator.org/ein/920240717